Clinical trials: Signet Ring Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be…
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum
- Trial name
- NCT01652196
- Testing
- aflibercept, oxaliplatin, leucovorin
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- John Hays
Colorectal Cancer
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01079780
- Testing
- cetuximab, ramucirumab, irinotecan hydrochloride
- Where
- 255 sites in United States
- Volunteers
- 136 people
- Sponsor
- Eastern Cooperative Oncology Group
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT01285102
- Testing
- irinotecan-eluting beads, hepatic artery embolization
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00100841
- Testing
- cetuximab, bevacizumab, oxaliplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01814501
- Testing
- panitumumab, irinotecan hydrochloride, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- John Hays
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT00835679
- Testing
- cetuximab, dasatinib, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)